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Receptor membrane components 
a b s t r a c t 
A previous investigation showed that the endometrium nor- 
malized in women with endometrial hyperplasia after three 
months treatment with high dose levonorgestrel IUS (in- 
trauterine system) [1] . The effect was maintained even if 
immunohistochemical analyses of the endometrium showed 
that nuclear progesterone receptors (nPRs) were completely 
downregulated. These observations indicated that some type 
of non-genomic effect existed [2] . We conducted new in- 
vestigations of endometrial hyperplasia, now with 6 months 
low dose levonorgestrel IUS treatment. Again, the growth 
disturbances were reversed with normalization of the en- 
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dometrium [ 3 , 4 ]. In the context of these studies, RT-qPCR 
analyses of the endometrium were performed before and 
after treatment, to determine expression of nuclear pro- 
gesterone receptors (nPRA + B and nPRB), membrane pro- 
gesterone receptors (mPR, α-, β- and γ -subtypes) and 
progesterone receptor membrane components (PGRMC1and 
PGRMC2). The human cervical cell line (C-4 I) [5] with no 
detectable nPRs [ 6 , 7 ] , was included in the investigation as 
biological control .The gene expression of nPRs, mPRs and 
PGRMCs was determined in the logarithmic growth phase. 
Tissue and cellular mRNA was determined with RT-qPCR and 
used as a surrogate marker for receptor (protein) expression. 
The present data are connected to the related article entitled 
“Expression of nuclear progesterone receptors (nPRs), mem- 
brane progesterone receptors (mPRs) and progesterone re- 
ceptor membrane components (PGRMCs) in the human en- 
dometrium after 6 months levonorgestrel low dose intrauter- 
ine therapy” [8] . 
© 2020 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY license. 





Subject Molecular Biology 
Specific subject area mRNA and gene expression of progesterone receptors and receptor membrane 
components 
Type of data Table 
Chart 
Graph 
How data were acquired RT-qPCR (Reverse transcription polymerase chain reaction) 
Instruments: Experion TM electrophoresis system (Bio-Rad, Hercules, CA, USA), 
NanoDrop 20 0 0c spectrometer (Thermo Scientific, Wilmington, DE, USA), 
CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA, USA), Software: 
qBase, geNorm 
Data format Raw and analyzed 
Parameters for data collection Endometrial biopsies from women with endometrial hyperplasia were 
obtained before end after treatment with levonorgestrel intrauterine device. 
The human cervical cell line (C-4 I) were expanded and harvested during 
logarithmic growth. Expression of genes for nuclear progesterone receptors, 
membrane progesterone receptors and progesterone receptor membrane 
components were evaluated. 
Description of data collection Total RNA were extracted from human endometrium and human C-4I cells to 
perform RT-qPCR 
Data source location UiT - The Arctic University of Norway, Tromsø, Norway 
Data accessibility The data are hosted in a public repository 
( Mendeley Data ):https://data.mendeley.com/datasets/4fwxby52h9/1 
Related research article E.T.Sletten, N. Smaglyukova. A.Ørbo and G.Sager, Expression of nuclear 
progesterone receptors (nPR), membrane progesterone receptors (mPR) and 
progesterone receptor membrane components (PGRMC) in the human 
endometrium after 6 months levonorgestrel low dose intrauterine therapy, 
Journal of Steroid Biochemistry and Molecular Biology 
https://doi.org/10.1016/j.jsbmb.2020.105701 
alue of the Data 
• The regulation of receptors that activate signal pathways of progesterone and gestagens are
incompletely understood 
• The present data will be useful for scientists in the basic and clinical research of progesterone
biochemistry, physiology and pharmacology 
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Fig. 1. Experimental design for RT-qPCR analysis of nPR (nuclear progesterone receptors), mPr (membrane progesterone 
receptors) and PGRMC (progesterone receptors membrane components) gene expression (mRNA). 
Fig. 2. Stability of reference genes tested for endometrial biopsies. B2M (Beta-2-Microglobulin), POLR2A (RNA Poly- 
merase II Subunit A), GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase), HPRT1 (hypoxanthine phosphoribosyltrans- 










• The present data represent a potential tool for scientists to characterize the complex interplay
between nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) 
and progesterone receptor membrane components (PGRMCs) [ 9 , 10 ] 
• The data can lead to development of new experiments to extend the knowledge of the reg-
ulation of nuclear as well as membrane progesterone receptors under various physiological
conditions and under influence of pharmacological substances i n vivo and in vitro 
1. Data Description 
The present data are a result of the investigation of nPR, mPR and PGRMC gene expression
in human endometrium and in a human cancer cell line from the uterine cervix (C-4I) and
obtained according to the flowchart in Fig. 1 . Table 1 shows the gene symbols, NCBI genBank
accession numbers gene names, primer sequences, amplicon size and PCR efficiency. Fig. 2 shows
the difference in stability of reference genes tested for the analysis of endometrial biopsies. The
















































List of primers for reference genes employed in qPCR-analysis. For the cultured C-4I cells, a commercially available reference gene primer sets CYC 1, ATP5B, GAPDH, 18S, ACTB and UBC 










GAPDH NM_001289745 Glyceraldehyde-3-phosphate dehydrogenase 5 ′ GAGCGAGATCCCTCCAAAAT3 ′ 
5 ′ AAATGAGCCCCAGCCTTCT3’ 
101 90.8 
HPRT1 NM_0 0 0194 Hypoxanthine phosphoribosyltransferase 1 5 ′ CTAATTATGGACAGGACTGAAC3 ′ 
5 ′ AGCAAAGAATTTATAGCCCC3 ′ 
108 99.1 
PGK1 NM_0 0 0291 Phosphoglycerate kinase 1 5 ′ CTAAGCAGATTGTGTGGAATG3 ′ 
5 ′ CTCACATGGCTGACTTTATC3 ′ 
187 94.9 
POLR2A NM_0 0 0937 Polymerase II subunit A 5 ′ GAATACCTTCCACTATGCTG3’ 
5 ′ AGAATATCCTTGGCTCTCTC3’ 
162 –
B2M NM_004048 Beta-2-microglobulin 5 ′ TCATCCACCAGCAGAGAATGGAA3’ 
5 ′ TCTGAATGCTCCAGTTTTTCAA3’ 
126 –
CYC 1 NM_001916 Cytochrome-c1 95.8 
ATP5B NM_001686 ATP synthase, H + transporting, mitochondrial 
F1 complex, beta polypeptide 
93.7 
GAPDH NM_001289745 Glyceraldehyde-3-phosphate dehydrogenase –
18S X03205 18S ribosomal RNA –
ACTB NM_001101 Actin beta –
UBC NM_021009 Ubiquitin C –
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Fig. 3. Stability of reference genes tested for C-4I cells. UBC (ubiquitin C), ACTB (Actin Beta), 18S (18S ribosomal RNAs), 



















HPRT1 and PGK1) were used for normalization ( Table 1 ). Fig. 3 shows the difference in stability
of reference genes tested for the analysis of C-4I cells. The order of stability was ATP5B = CYC
1 = GAPDH > 18S > ACTB > UBC. In the analyses CYC 1 and ATP5B were selected as reference
genes for normalization control of C-4I cells ( Table 1 ). 
Table 2 shows the primers used for detection of PRA + PRB, PRB, mPR α, mPR β , mPR γ ,
PGRMC1, PGRMC2 by RT-qPCR, in addition to gene symbols, NCBI genBank accession numbers,
gene names, primer sequences, amplicon size and PCR efficiency. The corrected normalized rel-
ative quantity (CNRQ) was calculated for each gene and scaled to the average value. 
2. Experimental design, materials, and methods 
2.1. Experimental design 
Fig. 1 shows a flowchart for the experimental design of RT-qPCR analysis of nPRs (nuclear
progesterone receptors), mPRs (membrane progesterone receptors) and PGRMCs (progesterone 
receptor membrane components) gene expression (mRNA). 
2.2. Materials 
Endometrial biopsies with analyzable tissue samples were obtained from 42 women. A group
of women ( n = 61) was recruited to a prospective, multicenter pilot investigation to assess the
efficacy of LNG-IUS 13.5 mg (Jaydess TM , Bayer Pharmaceuticals, Berlin, Germany) for treatment of
endometrial hyperplasia. Only those women ( n = 49) with a completed treatment period of six
months were included in the present work. In seven of the 49 women, endometrial biopsy ma-
terial was insufficient for qPCR analysis. Endometrial biopsies were obtained by an endometrial
suction cuvette (Pipelle TM , Laboratoire CCD, Paris, France) or dilatation and curettage or hys-
teroscopic transcervical resection. All endometrial tissue specimens (baseline and post therapy
biopsies) were conserved in RNAlater stabilization solution (Ambion RNAlater TM , ThermoFisher
Scientific, Whatham, MA , USA , code AM7021) and immediately frozen and kept at-18 °C until

























































PRA + PRB NM_001202474 Homo sapiens progesterone receptor 
(PGR), transcript variant 1, mRNA 
5 ′ AGGTCTACCCGCCCTATCTC3’ 
5 ′ TCCCACAGGTAAGGACACCA3’ 
150 93.5 
PRB NM_0 0 0926 Homo sapiens progesterone receptor 
(PGR), transcript variant 2, mRNA 
5 ′ GCACGAGTTTGATGCCAGAGA3’ 
5 ′ CTGCGACGGCAATTTAGTGA3’ 
69 98.4 
mPR α NM_178,422 Progestin and adipoQ receptor family 
member 7 (PAQR7) 
5 ′ CGCTCTTCTGGAAGCCGTACATCTATG3 ′ 
5 ′ CAGACGGTGGGTCCAGACATTCAC3 ′ 
121 110.6 
mPR β NM_133,367 Progestin and adipoQ receptor family 
member 8 (PAQR8) 
5 ′ GTCCATCTGTACGCTCTCCC3 ′ 
5 ′ GCAGGCCATGTGGACAGATA3 ′ 
106 95.9 
mPR γ NM_017705 Progestin and adipoQ receptor family 
member 5 (PAQR5) 
5 ′ CAGCTGTTTCACGTGTGTGTGATCCTG3 ′ 
5 ′ GGACAGAAGTATGGCTCCAGCTATCTGAG3 ′ 
144 99.8 
PGRMC1 NM_006667 Progesterone receptor membrane 
component 1 
5 ′ TGACCTTTCTGACCTCACTGC3’ 
5 ′ GCCCACGTGATGATACTTGA3’ 
85 93.4 
PGRMC2 NM_006320 Progesterone receptor membrane 
component 2 
5 ′ TCGAGAATGGGAAATGCAG3 ′ 
5 ′ TTGTGATCCTTGGTATCTTCTTCA3 ′ 
111 92.8 














































The human cell line C-4I (ATCC, CRL -1594 TM ) was derived from a squamous carcinoma of
the uterine cervix [5] and obtained from the American Type Culture Collection (Rockville, MD,
USA). The cells were cultured in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA, code R8758)
with 10% (v/v) fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA, code F7524 ), 1% Penicillin-
Streptomycin with 10,0 0 0 units penicillin and 10 mg streptomycin per mL in 0.9% NaCl (Sigma-
Aldrich, St. Louis, MO, USA, code P0781) at 37 °C in a humidified 5% CO 2 atmosphere in our
laboratory. The cells were seeded in six well plates at a density of 4 × 10 4 cells/mL in five paral-
lels. The medium was changed every second day and the cells were harvested in the logarithmic
phase of growth (five days after seeding). 
To collect the cultures for RNA extraction, media was removed by aspiration, and the cells
were brought into a suspension using 200 μL 0.25% (w/v) trypsin with 0.2% (w/v) Na 4 EDTA,
(Sigma-Aldrich, St. Louis, MO, USA, code T4049), and the trypsin activity was terminated by
addition of 800 μL of incubation media. The cell counts were obtained (Contess Automated Cell
Counter TM , Invitrogen, ThermoFisher Scientific, Carlsbad, CA, USA) and the cells were conserved
in RNA stabilization solution (Ambion RNAlater TM , ThermoFisher Scientific, Whatham, MA , USA ,
code AM7021), stored at 4 °C overnight and then transferred to −20 °C until further analysis. 
2.3. Methods 
The first step was RNA isolation and cDNA synthesis. Total RNA extraction from endome-
trial tissue samples and C-4I cells was performed using a commercial RNA extraction kit (Bio-
Rad Aurum Total RNA Mini Kit, BIO-RAD, Hercules, CA , USA , code 732–6820). RNA was iso-
lated according to manufacturer’s instruction manual. Tissue samples (10–30 mg) were trans-
ferred to MagNA Lyser Green Beads tubes (Roche Molecular Biochemicals, Mannheim, Germany).
Lysis buffer (700 μL) from RNA isolation kit, containing 1% (v/v) β-mercaptoethanol (BioRad,
Hercules, CA , USA , code 1,610,710), was added to the tubes. The samples were homogenized
in a Precellys TM 24 high-throughput homogenizer (Bertin Technologies, Rockville, MD, USA) at
60 0 0 × g for 30 s and cooled on ice for 2 min. Afterwards, the samples were left at room tem-
perature for 5 min. RNA was eluted and stored at −70 °C. 
RNA quality was evaluated with the Experion TM electrophoresis system (Bio-Rad, Hercules,
CA, USA) using the Experion TM RNA StdSens Analysis Kit (Bio-Rad Laboratories, Hercules, CA
USA, code 7,007,104). RNA samples isolated from patient biopsies and from cultured cells were
examined for concentration, purity and integrity. The concentrations and the purity of RNA were
determined using NanoDrop 20 0 0c spectrometer (Thermo Scientific, Wilmington, DE, USA). The
endometrial RNA samples showed A260/280 ratio of 2.1 ± 0.023 (mean ± SD) and a RNA in-
tegrity of 8.5 ± 0.9 (mean ± SD). The A260/280 ratio of the C-4I cell RNA samples was 2.1 ± 0.012
(mean ± SD) and with a RNA integrity of 9.9 ± 0.1 (mean ± SD). 
The concentration of RNA was measured using NanoDrop 20 0 0c spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). Reverse transcription was performed using iScript TM cDNA Syn-
thesis Kit (Bio-Rad, Hercules, CA , USA , code 170–8891). A total of 500 ng RNA was reverse tran-
scribed in a final volume of 20 μL. After the synthesis, cDNA was diluted 10 x with nuclease free
water (Promega, Madison, WI, USA, code P1195). The cDNA was stored at −20 °C for further use.
The next step was analysis of reference gene stability, selection of primers and reaction ef-
ficiency. The most stable reference genes were chosen for normalization calculations in qBase
program. Predesigned reference genes were obtained from Sigma-Aldrich (Haverhill, UK) and
Primerdesign Ltd (Southampton, UK). The geNorm program ( https://genorm.cmgg.be ) was used
to find the most stable gene transcript of reference genes for normalization controls. In the qPCR
analyses, several reference genes belonging to different functional classes were evaluated by
the geNorm software. For the endometrial biopsies five reference genes (B2M, POLR2A, GAPDH,
HPRT1 and PGK1) were examined. Six genes (UBC, ACTB, 18S, GAPDH, CYC1 and ATP5B) were
evaluated as reference genes for C-4I cells. Pairwise variation (Vn/ n + 1) geNorm V analysis was
carried out to determine the number of reference genes required for normalization. In the case
of C-4I cells, the optimal number was two reference genes, Cyc1 and ATP5B. 







































PRA + PRB, PRB and mPR β primers were designed using Primer-blast on the NCBI website
 http://blast.ncbi.nlm.nih.gov/ ). The design of mPR α and mPR γ primers was performed as de-
cribed by Dressing and Thomas [11] and those for PGRMC1 and PGRMC2 as described by Causey
t al. [12] .The sequences of primers are listed in Table 2 . 
A standard curve from a twofold serial dilution of pooled cDNA was made and gave a high
T-qPCR reaction efficiency of the primer pairs, shown in Table 1 and Table 2 , respectively. A
ene-specific amplification was confirmed by a single peak in the melting curve analysis. 
Real-time qPCR was carried out using the CFX96 real-time PCR detection system (Bio-Rad,
ercules, CA, USA) and SsoAdvance Universal SYBR Green Supermix (BIO-RAD, Hercules, CA, USA,
ode 172–5271) and human SYBRgreen reference gene detection kit. 900 reaction (Primerdesign
td., Southampton, UK, code HK-SY-hu-900). The assay was run with 2.5 μL of 10 × diluted cDNA
n a 10 μL total reaction supermix. The thermal profile for SYBR real-time qPCR included an ini-
ial heat-denaturing step at 95 °C for 30 s, 40 cycles at 95 °C for 5 s and 60 °C for 30 s. Following
mplification, a melt-curve analyses of the PCR products were performed from 65 °C to 95 °C
o determine the specificity of amplification. Each sample was run in duplicate. A non-template
ontrol and an inter-run calibrator were added to each run. Data acquisition and subsequent
ata analyses were performed using the CFX Manager software (Bio-Rad, Hercules, CA, USA).
ene expression was analyzed with qBase software as described by Hellemans et al. [13] .The
rogram employs a modified delta-Ct method with the possibility to adjust for PCR efficiency
nd to use multiple reference genes for normalization. The corrected normalized relative quan-
ity (CNRQ) was calculated for each gene and scaled to the average value. 
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